# Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

> **NCT02957656** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 53 (actual)

## Conditions studied

- Influenza A Virus, H7N9 Subtype

## Interventions

- **BIOLOGICAL:** H7N9 pLAIV
- **BIOLOGICAL:** H7N9 pIIV
- **BIOLOGICAL:** AS03 adjuvant

## Key facts

- **NCT ID:** NCT02957656
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-06
- **Final completion:** —
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957656, "Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02957656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*